NASDAQ:AXLA - Nasdaq - US05454B2043 - Common Stock - Currency: USD
Overall AXLA gets a fundamental rating of 0 out of 10. We evaluated AXLA against 551 industry peers in the Biotechnology industry. Both the profitability and financial health of AXLA have multiple concerns. AXLA does not seem to be growing, but still is valued expensively.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -518.6% | ||
ROE | N/A | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | N/A | ||
Debt/FCF | N/A | ||
Altman-Z | -78.43 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 0.81 | ||
Quick Ratio | 0.81 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
4.58
-0.9 (-16.42%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | N/A | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | N/A | ||
P/tB | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -518.6% | ||
ROE | N/A | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | N/A | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 85.19% | ||
Cap/Sales | N/A | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 0.81 | ||
Quick Ratio | 0.81 | ||
Altman-Z | -78.43 |